Xilia-MP 1 Tablet PR is a combination oral antidiabetic medication containing Glimepiride (1mg), Metformin (500mg), and Pioglitazone (15mg), indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea, stimulates pancreatic beta cells to enhance insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, contributing to better glycemic control. Pioglitazone, a thiazolidinedione, acts as an insulin sensitizer by activating peroxisome proliferator-activated receptor gamma (PPAR-γ), which enhances glucose uptake in adipose tissue and muscle. The combined action of these agents provides complementary mechanisms to achieve effective glycemic regulation in patients inadequately controlled by monotherapy or dual therapy. Xilia-MP 1 Tablet PR is administered orally, usually once daily with meals to minimize gastrointestinal side effects. It is essential to monitor blood glucose levels regularly and adjust the dosage based on therapeutic response and tolerability. Contraindications include type 1 diabetes, diabetic ketoacidosis, severe renal or hepatic impairment, and hypersensitivity to any components. Common adverse effects may include hypoglycemia, gastrointestinal disturbances, weight gain, and edema. This combination therapy should be used under medical supervision with appropriate lifestyle modifications for optimal diabetes management.